Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial.
Moderna, a pharmaceutical company intricately tied to vaccine technology for pandemics, has announced its plans to move forward with Phase 3 trials for its novel combination injection of seasonal influenza and COVID-19 vaccines, following what they describe as “strong” results in the Phase 1/2 testing.
This marks a significant relief for the biotech firm, as it had previously experienced disappointment with its earlier combination vaccine, mRNA-1010, during this stage of testing.
Moderna’s CEO, Stéphane Bancel, stated on Wednesday, October 4th, “With today’s positive outcomes for our influenza and COVID-19 combo vaccine, we are set to expand our Phase 3 product lineup. The combination vaccine presents a crucial opportunity to enhance the consumer and healthcare provider experience, improve adherence to public health recommendations, and deliver value to the healthcare system. We are excited to advance the respiratory combo vaccine to the Phase 3 development stage.”
The safety and immunogenicity of the mRNA-1083 vaccine were compared through a randomized, observer-blinded study against the standard flu vaccine, Fluarix, and the enhanced flu vaccine, Fluzone HD, with the former intended for adults aged 50-64 and the latter for those aged 65-79. In both age groups, mRNA-1083 was compared to Moderna’s latest COVID-19 vaccine, Spikevax booster shots.
Moderna reports that the “obtained titers of neutralizing antibodies were similar to or higher than those obtained with two licensed quadrivalent influenza vaccines, and the obtained titers of SARS-CoV-2 neutralizing antibodies were similar to Spikevax two-dose booster.”
In terms of adverse effects, adverse events observed in the trial were similar to those seen with standalone COVID-19 vaccines, mostly mild (Grade 1 or 2) in nature, with less than 4% of individuals reporting more severe Grade 3 events. No new safety concerns were identified for the new combination vaccine.
Moderna plans to initiate Phase 3 trials for mRNA-1083 by the end of this year and aims to secure regulatory approval by 2025.
Bancel added, “We are pleased to advance the respiratory combo vaccine into Phase 3 development and look forward to collaborating with public health officials in addressing the significant seasonal threats these viruses pose to humanity.”
Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
